LipocineLPCN
13F holders, Q1 2025 (March 31)19holders +2
2new positions
0sold out
1famous investor
$3.18avg. 13F price*
At the end of Q1 2025, 19 institutions reported holding Lipocine Inc. (LPCN) in their 13F filings, up 2 from Q4 2024. 2 opened new positions and 0 sold out. The largest holders were Vanguard Group Inc. ($720K), BlackRock, Inc. ($284K) and Geode Capital Management, LLC ($187K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Lipocine Inc.
- CUSIP
- 53630X203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $401 |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 31,091 shares bought and 289 shares sold, net +30,802 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| Vanguard Group Inc. | 0.00% | Add +2.2% | 226,276 | $720K |
| BlackRock, Inc. | 0.00% | No change | 89,272 | $284K |
| Geode Capital Management, LLC | 0.00% | Add +2.4% | 58,834 | $187K |
| Susquehanna International Group, LLP | 0.00% | Add +55.9% | 38,980 | $124K |
| Renaissance Technologies | 0.00% | Add +4.1% | 37,510 | $119K |
| Dimensional Fund Advisors LP | 0.00% | Add +21.5% | 24,935 | $79K |
| State Street Corp. | 0.00% | No change | 18,626 | $59K |
| Northern Trust Corp. | 0.00% | No change | 13,160 | $42K |
| Bank of America Corp. | 0.00% | Add +4062.9% | 2,581 | $8K |
| Morgan Stanley | 0.00% | Reduce -2.2% | 2,575 | $8K |
| Osaic Holdings, Inc. | 0.00% | Add +889.4% | 2,246 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -15.6% | 1,237 | $4K |
| Caldwell Sutter Capital, Inc. | 0.00% | No change | 471 | $1K |
| FMR LLC | 0.00% | Add +264.6% | 237 | $754 |
| UBS Group AG | 0.00% | Add +6533.3% | 199 | $632 |
| Group One Trading LLC | 0.00% | No change | 197 | $626 |
| SBI Securities Co., Ltd. | 0.00% | New | 67 | $213 |
| Tidemark, LLC | 0.00% | New | 59 | $188 |
| JPMorgan Chase & Co. | 0.00% | Reduce -8.3% | 11 | $35 |
"% of holder's portfolio" is LPCN's weight in each manager's 13F, not the share of Lipocine Inc. the manager owns.